Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft Academic Article uri icon

Overview

MeSH Major

  • Graft Rejection
  • Immunoglobulins, Intravenous
  • Kidney Transplantation
  • Plasma Cells

abstract

  • Plasma cell-rich acute rejection (PCAR) is associated with poor allograft outcome in renal transplantation. Previous studies report a graft half-life of six months after a single PCAR episode. However, the management of this condition is unclear. Intravenous immunoglobulin (IVIG) therapy, by virtue of its immunomodulating properties, and its influence on B-cell maturation into plasma cells, may be a good candidate for reversing this type of rejection. We report four episodes of PCAR in two patients who responded well to IVIG with improvement in renal function.

publication date

  • August 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/01.tp.0000231922.11453.ec

PubMed ID

  • 16926602

Additional Document Info

start page

  • 567

end page

  • 9

volume

  • 82

number

  • 4